Précis: Non-invasive biomarkers offer critical tools for clinical trials of targeted drugs, as illustrated in this study providing mechanistic support for the use of phosphocholine as a candidate non-invasive biomarker for imaging the pharmacodynamic response to HDAC inhibitors.
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INTRODUCTION
Histone acetylation is a key regulator of eukaryotic gene expression which controls DNA accessibility to transcription factors and mRNA transcription. The histone acetylation/deacetylation balance is maintained by the opposing activities of histone acetyl transferases and histone deacetylases (HDACs) resulting in cell-specific gene expression patterns (1) . Deregulation of histone acetylation results in abnormal gene expression profiles involved in controlling cell proliferation, differentiation and apoptosis, and is associated with malignancy (2-5).
HDACs also act on other non-histone proteins that are subject to regulation by acetylation including some transcription factors (e.g. E2F) and the heat shock protein 90 (HSP90) molecular chaperone, which maintains the conformational stability of several oncogenic proteins (e.g. ErbB2) (6) .
HDAC inhibition is a promising anti-tumor approach for simultaneously targeting multiple oncogenic players and pathways. Several HDAC inhibitors have been described that induce potent anti-tumor effects in cells and tumor xenografts (6) (7) (8) . The HDAC inhibitors SAHA (vorinostat) and depsipeptide FK228 (romidepsin) have gained FDA approval for cutaneous T-cell lymphoma treatment and many more are currently under clinical evaluation (6;8-11) . One example is belinostat which has shown promising activity in pre-clinical cancer models and in patients (8;12) . The development and evaluation of novel HDAC inhibitors requires the identification and validation of pharmacodynamic (PD) biomarkers of drug activity. These are important because they inform on the inhibition of the intended biochemical target, help assess response dynamics, aid treatment schedule and dose planning, and subsequently allow therapeutic efficacy assessment (13) (14) (15) . In contemporary drug development, noninvasive endpoints of target modulation are highly desirable as they do not involve surgical intervention and allow longitudinal studies in the same patient to be performed (15) (16) (17) .
Non-invasive imaging of cancer metabolism is a valuable approach for PD biomarker discovery that exploits the altered metabolic features of tumors relative to normal tissues, including increased lipid synthesis and aerobic glycolysis (18;19). These metabolic changes are increasingly being investigated as diagnostic as well as treatment response biomarkers, with techniques such as magnetic resonance spectroscopy (MRS) being of particular value for translating findings from pre-clinical models to humans (16;17;20-22) .
MRS allows the detection of many metabolites (e.g. those related to glucose, protein and lipid metabolism), and in pre-clinical studies has shown that response to molecularlytargeted therapeutics is often associated with altered metabolism (17;20) . For example, inhibitors of HSP90 (23;24), phospholipase Cγ1 (25), mitogen activated protein kinase MEK (26) or phosphoinositide 3-kinase (27;28) have all been shown to alter choline phospholipid metabolism in human cancer cells. In the case of the HDAC inhibitor 6 LAQ824, in vitro and in vivo MRS showed increased phosphocholine (PC) levels both in human colon cancer cells and tumors post-treatment (29). A similar effect was also observed in human colon and prostate cancer cells treated with the HDAC inhibitor SAHA (29) or its fluoro-analogue (30), respectively. Furthermore, LAQ824 treatment caused a substantial reduction in tumor bioenergy-related metabolites (e.g. NTP, glucose) that was observed in vivo but not in vitro (29). This effect was attributed to the antiangiogenic action of LAQ824, while the rise in PC was likely to relate to the effect of HDAC inhibition on tumor cell metabolism (29) although the molecular and biochemical mechanisms behind this change remain unclear.
Here we assess i) whether similar metabolic effects would be observed with the alternative chemotype (chemical scaffold) HDAC inhibitor and probe compound belinostat, and ii) the molecular and biochemical processes underlying the observed metabolic alterations.
We show that HDAC inhibition with belinostat in human cancer cells leads to increased alanine and branched-chain amino acid (BCAA) content that was associated with altered glucose utilization. Belinostat also increased PC levels, thus confirming our previous finding with the alternative chemotype agent LAQ824. Importantly, we show for the first time that this effect is associated with induction of choline kinase α (ChoKα) gene and protein expression. The increase in PC is also observed in belinostat-treated tumors in vivo, thus supporting the role of PC as a potential non-invasive metabolic imaging biomarker of HDAC inhibition.
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MATERIALS AND METHODS
Cell culture
Human HT29 colon and PC3 prostate carcinoma cells (ATCC) were grown in DMEM or RPMI, respectively, containing 10% FBS, 100U/ml penicillin and 100μg/ml streptomycin in a 37°C humidified 5% CO 2 atmosphere. Cells were preserved and propagated according to ATCC's protocols, screened monthly for mycoplasma and passaged for no longer than three months. All cell culture materials were from Life Technologies (Paisley, UK).
Western blotting
Analysis of the molecular effects of HDAC inhibition was performed using Western blotting as previously described (29). The primary antibodies rabbit anti-acetyl histone-3 (Millipore; Watford, UK), rabbit anti-choline kinase alpha (ChoKα, Sigma-Aldrich; Dorset, UK), mouse anti-GAPDH (Chemicon; Hampshire, UK) and rabbit α-tubulin (Cell Signaling Technology; Danvers, MA, USA) were used. The secondary anti-rabbit and anti-mouse antibodies were from GE Healthcare Life Sciences (Buckinghamshire, UK).
Growth inhibition and cell cycle analysis
Cell counts were performed on a Beckman Coulter Vi-Cell® Cell Viability Analyzer.
The impact of belinostat on cell proliferation and cell cycle distributions was assessed using the sulforhodamine B (SRB) assay and flow cytometry, respectively, as previously described (27).
Cell treatment for in vitro MRS
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PC3 and HT29 cells were treated for 24h with belinostat (0.9μM and 2μM, respectively), to obtain a 30-50% reduction in cell counts and induction of histone-3 acetylation as a characteristic molecular biomarker of HDAC inhibition (9) . HT29 cells were further treated with 2μM belinostat for 4h and 16h to assess response time dynamics. Control cells were treated with 0.01% DMSO. At the end of treatment, cells were extracted using a dual phase method (26), and samples lyophilized for MRS analysis.
Quantitative real time (qRT) PCR
Total RNA was extracted using the RNAeasy kit (Qiagen; Crawley, West Sussex, UK) and 500 nanogram was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Carlsbad, California, USA). Samples were diluted 1:5 and 1µl used in the Taqman assay, using Taqman universal master mix, and the Hs03682798_m1 assay for the ChoKα gene CHKA (CHKA specific primers and FAM labeled probe) multiplexed with the 4326314E assay for large ribosomal protein 0 gene LRP0 (LRP0 specific primers and VIC labeled probe, Applied Biosystems). mRNA levels of CHKA and LRP0 were determined for each sample in the same well on the ABI 7900HT. CHKA mRNA levels were expressed relative to those of LRP0.
Research. ) was established (3-4 weeks later), mice were randomized into two groups; one group was treated with belinostat in vehicle (10% DMSO in water) at 60mg/kg p.o. once a day for 3 days (days 1, 2 &3, n=13), and one group was treated with vehicle alone (n=12). A cohort of animals (6 vehicle-and 6 belinostat-treated) was used in the MRS study, and tumors were excised on day 3 for Western blotting or in vitro MRS. Another animal cohort (6 vehicle-and 7 belinostat-treated) was used to study tumor growth delay where animals were treated as above and tumor volumes monitored for a further 6 days after the last dose. Animals were treated in accordance with local and national ethical requirements and with the UK National Cancer Research Institute (NCRI) Guidelines for the Welfare and Use of Animals in Cancer Research (31).
In vivo MRS of HT29 tumors
Mice were anesthetized as previously described (29) 
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The surface coils used to obtain the 31 P MRS signal from subcutaneous tumors in vivo have a non-uniform spatial sensitivity making it difficult to normalize to an external standard. Therefore, the signal intensities observed by in vivo 31 P MRS are expressed as metabolite ratios.
In vitro MRS of tumor extracts
Freeze-clamped HT29 tumors (~200mg) were extracted in 6% ice-cold PCA as previously described (29). Neutralized extracts were freeze-dried and reconstituted in 1ml of D 2 O and 0.5ml was then analyzed. Sodium 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate (TSP; 50μl, 5mM) was added as an internal chemical shift and quantification reference. The pH of the samples was re-neutralized with PCA or KOH followed by acquisition of water-suppressed 1 H MRS spectra. For 31 P MRS, EDTA (50μl, 60mM) was added to chelate metals ions, and methylenediphosphonic acid (internal reference; 50μl, 5mM) was added.
In vitro MRS of cell extracts and media samples
Lyophilized samples of the aqueous fraction of cell extracts were processed as above.
The lipid phase of cell extracts was reconstituted in CDCl 3 containing 0.56mM trimethyl silane (internal standard). Media samples from the [1- P spectra were acquired as previously described (23). 13 C MR spectra were acquired using power gated composite pulse 1 H decoupling, a 30º flip angle, a 2s repetition delay, a spectral width of 220ppm and 32K data points. Spectral processing and metabolite quantitation were performed as previously described (23).
Research. 
Statistical analysis
Statistical significance was assessed using Student's t-tests with p≤0.05 considered to be significant. Pearson correlation analysis was performed using GraphPad Prism version 5.01. Data represent the mean±SE.
RESULTS
Belinostat treatment alters cellular metabolism in human HT29 and PC3 carcinoma cells
Belinostat inhibited proliferation in HT29 colon and PC3 prostate cancer cells as shown by the SRB assay (Table S1 ). The respective exposure of HT29 and PC3 cells to 2μM 
HDAC inhibition with belinostat alters glucose utilization
To investigate the basis for the rise in amino acid (AA) levels, HT29 cells were cultured in the presence of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]-glucose for 3h to monitor tracer uptake and incorporation into glycolytic intermediates. 13 C MRS of cell extracts indicated that, following belinostat treatment, no significant effects were observed on intracellular 13 C-glucose levels; however, extracellular [3- Altogether, these data suggest that belinostat treatment induced a shift in glucose routing, leading to a reduction in glucose flux to lactate in favor of a rise in alanine formation.
HDAC inhibition with belinostat increases de novo PC synthesis and induces ChoKα expression
To investigate the basis for the PC rise, HT29 cells were cultured in the presence of [1,2- Figure 3A and B, p=0.01). This degree of increase is comparable to the fold rise in PC recorded by 31 P and 1 H MRS, suggesting that the effect on the steady state levels of this metabolite is due to increased de novo formation.
To characterize the molecular drivers of this effect, we assessed the expression of ChoKα, the enzyme that catalyses the formation of PC from its precursor choline. qRT-PCR analysis indicated that following belinostat treatment the levels of ChoKα mRNA were induced by 2.3-fold at 4h, 3.5-fold at 16h and 3.2-fold at 24h relative to controls in HT29 cells ( Figure 3C ) and this effect correlated strongly with the increase in PC levels observed by MRS (r=0.99, p=0.02). ChoKα mRNA was also induced to 148±8% relative to controls (n=9, p=0.002) in PC3 cells following a 24h treatment with belinostat.
Western blotting of the HT29 cell samples from the 13 C-choline labeling experiment showed induction of ChoKα protein expression up to 260±45% (n=3, p=0.018) of controls following exposure to belinostat ( Figure 3D ).
HDAC inhibition with belinostat increases levels of choline-containing metabolites of HT29 xenografts in vivo
To assess if any of the metabolic alterations observed in cells would be translatable to in vivo tumor models, we evaluated the metabolite profiles of HT29 tumor xenografts following treatment with belinostat. 
In vivo
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P MR spectra from a HT29 tumor pre-and post-belinostat treatment are shown in Figure 4C (right panel), where resonances from phosphomonoesters (PME), phosphodiesters (PDE), inorganic phosphate (Pi), α-, β-, γ-NTP and phosphocreatine (PCr) can be observed. Significant increases in PME/TotP (total phosphorus signal) (p=0.01) and Pi/TotP ratios (p=0.03) were observed post-belinostat treatment (Table 2A) .
No significant change in metabolite ratios was observed in the vehicle-treated group (Table 2B) .
Research. (Table 3B) relative to controls, consistent with the in vivo cells in vitro and in vivo in addition to PC3 human prostate cancer cells in vitro, and ii) investigate the mechanism(s) underlying this effect.
The clinical development of belinostat is now primarily directed towards the use of this drug in combination with chemotherapy. In this study belinostat served as an alternative chemotype probe to the agents currently in the clinic. Probe compounds have considerable value for interrogating the molecular function of target proteins and the downstream biological processes they mediate, and for biomarker discovery and validation (32).
HT29 and PC3 cells were treated in vitro with belinostat at a concentration and duration that led to target modulation (shown by histone-3 hyperacetylation) and inhibition of cell proliferation (shown by SRB assays and cell counts).
P MRS metabolic analysis under these conditions indicated that the most significant effect observed in both HT29 and PC3 cells after 24h of treatment was a rise in PC content, which was time-dependent in HT29 cells. When detectable (in HT29 cells), GPC levels decreased post-belinostat treatment.
The changes in PC and GPC were confirmed by 1 H MRS which also indicated that the tCho signal was also significantly higher following belinostat treatment in both cell lines.
The rise in PC is in line with our previous findings with LAQ824 and SAHA in HT29 cells (29) indicating that it is not inhibitor chemotype-specific or cell line/tissue typedependent.
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Furthermore, belinostat treatment resulted in increased BCAAs, alanine and threonine levels in both HT29 and PC3 cells as shown by 1 H MRS. These changes were also timedependent in HT29 cells.
Next we set out to investigate the metabolic processes underlying the increases in AA and PC levels following HDAC inhibition. An increase in AAs could reflect i) elevated uptake, ii) increased de novo formation from glycolytic intermediates or other AAs, iii) increased proteolysis, iv) decreased utilization (e.g. in protein synthesis), or a combination of the above.
Measurement of HT29 cell lysates by the BIO-RAD method revealed a 10% rise in protein content of belinostat-treated cells relative to controls (data not shown). Therefore
it is unlikely that the rise in AAs observed here could reflect increased proteolysis or decreased protein synthesis as this would be expected to reduce the overall cellular protein mass.
To assess whether AA rise was due to increased synthesis from glycolytic intermediates, we analyzed the 
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PtdCho-specific phospholipase C or release of choline from PtdCho via phospholipase D followed by ChoK-mediated phosphorylation (35).
To distinguish these two processes, we assessed levels of 
TABLES
